Busulfan-based reduced toxicity conditioning regimen used in hematopoietic stem cell transplantation in HLH patients results in sustained donor chimerism.

Goode, Erin; Miller, Holly; Salzberg, Dana; Campbell, Courtney; Beebe, Kristen; Schwalbach, Charlotte; Adams, Roberta H; Ngwube, Alexander

Goode, Erin; Miller, Holly; Salzberg, Dana; Campbell, Courtney; Beebe, Kristen; Schwalbach, Charlotte; Adams, Roberta H; Ngwube, Alexander.

Afiliação

Goode E; Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA.
Miller H; Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA.
Salzberg D; Mayo Clinic Arizona, Phoenix, AZ, USA.
Campbell C; Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA.
Beebe K; Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA.
Schwalbach C; Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA.
Adams RH; Mayo Clinic Arizona, Phoenix, AZ, USA.
Ngwube A; Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA.

Pediatr Hematol Oncol ; 38(4): 410-416, 2021 05.

Article em En | MEDLINE | ID: mdl-33625293

Assuntos

Bussulfano; Transplante de Células-Tronco Hematopoéticas; Quimerismo; Humanos; Condicionamento Pré-Transplante

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Bussulfano / Transplante de Células-Tronco Hematopoéticas Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google